Clinical Trial Update: Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating the combination of pembrolizumab and cabozantinib (Cabometyx) in patients with metastatic renal cell carcinoma; results h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Metastatic Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-10-17